BCIQ Profiles

Company Profile Report
1110 Lilly mAb
BioCentury & Getty Images

Product Development

Operation Warp Speed defends dosing for Lilly mAb, outlines distribution strategy

Warp Speed plans phased rollout for COVID mAbs

Warp Speed plans phased rollout for COVID mAbs

Nov 11, 2020 | 1:36 AM GMT

Trump administration officials Tuesday dismissed concerns that FDA may have authorized an ineffective dose of Lilly’s COVID-19 mAb and expressed confidence that bamlanivimab will have a substantial impact on the pandemic if and when healthcare systems come up with safe, effective ways to administer it.

In a briefing for

Read the full 870 word article